Although large-scale analysis of the tumor genome as a basis for treatment selection is promising indeed, it should be reminded that there are a number of complex layers of biology that attenuate or even completely remove the impact of genomic changes on outcome at the tissue and organism levels [3, 4], illustrated, for example by the different predictive impacts of BRAF mutations depending on tumor type [3]. This evidence concerns the gene BRAF and neoplasm.